{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-074775","form_type":"8-K/A","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.016274+00:00","generated_at":"2026-06-04T09:06:23.535924+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Homology Medicines: reverse stock split effective March 26; Nasdaq listing approved for combined company","bullets":["Reverse stock split at 1-for-18 ratio effective at trading open on March 26, 2024; new CUSIP 746964105.","Stockholders to receive cash for fractional shares based on March 25 closing price.","Nasdaq Staff approved initial listing application for continued listing of Homology common stock post-merger with Q32.","Reverse split is part of the merger with Q32 Bio Inc.; Q32 will survive as a wholly owned subsidiary."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-074775","json":"https://secwatch.observer/filing/0001193125-24-074775.json","markdown":"https://secwatch.observer/filing/0001193125-24-074775.md","text":"https://secwatch.observer/filing/0001193125-24-074775.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312524074775/0001193125-24-074775-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312524074775/d817398d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:06:23.535924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}